Amarin (AMRN) posts better-than-expected first-quarter 2024 results. Vascepa's sales in the United States continue to be hurt by generic competition.
AMRN earnings call for the period ending March 31, 2024.
Amarin (AMRN) secures a new patent for Vazkepa in Europe, which extends its exclusivity for eight more years. It achieves success in defending another patent on the drug against third parties.